Data / Federal awards / NAICS 541714 / THE INSTITUTE FOR CANCER RESEARCH
THE INSTITUTE FOR CANCER RESEARCH: 9 federal contract awards, $1.7 million obligated (FY2024 to FY2027)
Updated October 6, 2026. Source: USAspending.gov.
THE INSTITUTE FOR CANCER RESEARCH (UEI FF1XVJMDYVR1), Philadelphia, PA, received 9 federal prime contract awards with $1.7 million obligated in fiscal years 2024 to 2027, from 1 agency under 2 NAICS codes. Its largest buyer is Department of Health and Human Services ($1.7 million) and its largest code is NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The request: Every federal contract awarded under NAICS 541714, with the winner, the agency and the value. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every federal contract award on USAspending.gov and every open opportunity on SAM.gov, and this page is that reading. Ask for the awards in your niche and the winners, agencies, values and recompetes arrive in your sheet, CRM, Slack or agent as they are reported.
- UEI
- FF1XVJMDYVR1
- Location
- Philadelphia, PA
- Business size
- Other Than Small Business
- Contract awards
- 9
- Obligated
- $1.7 million
- First action in window
- 2023-11-06
- Latest action
- 2026-07-21
Where the work is
NAICS codes, with the other winners in each.
| NAICS | Industry | Awards | Obligated |
|---|---|---|---|
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | 8 | $1.7 million |
| 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | 1 | $-16,800 |
Buying agencies
| Agency | Awards | Obligated |
|---|---|---|
| Department of Health and Human Services | 9 | $1.7 million |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2024 | $1.7 million |
| FY2025 | $0 |
| FY2026 | $-16,800 |
Contract awards
All 9 awards in fiscal years 2024 to 2027.
| Award ID | Agency | Type | NAICS | What it buys | Obligated in window | Award value | Starts | Ends | Place of performance | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 75N91022F00001 | Department of Health and Human Services | Delivery Order | 541714 | BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINE | $1,436,985 | $2,051,148 | June 15, 2022 | May 14, 2027 | Philadelphia, PA | usaspending.gov |
| 75N91022F00003 | Department of Health and Human Services | Delivery Order | 541714 | TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTION PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLI | $245,908 | $948,377 | September 15, 2022 | June 14, 2026 | Philadelphia, PA | usaspending.gov |
| 75N91022F00002 | Department of Health and Human Services | Delivery Order | 541714 | TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER | $2,220 | $1,237,620 | May 18, 2022 | November 17, 2026 | Philadelphia, PA | usaspending.gov |
| 75N91023F00001 | Department of Health and Human Services | Delivery Order | 541714 | COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS | $0 | $1,038,958 | July 10, 2023 | July 9, 2027 | Philadelphia, PA | usaspending.gov |
| 75N91020F00001 | Department of Health and Human Services | Delivery Order | 541714 | TASK ORDER: PREVENTING LUNG CANCER BY TARGETING ACTIVATED STAT3 | $0 | $779,932 | September 21, 2020 | March 20, 2025 | Philadelphia, PA | usaspending.gov |
| 75N91019D00022 | Department of Health and Human Services | IDC | 541714 | PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS (POP: 01/25/2019 -01/24/2024 | $0 | $74,995,000 | January 25, 2019 | usaspending.gov | ||
| 75N91023F00003 | Department of Health and Human Services | Delivery Order | 541714 | PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVEN | $0 | $1,199,274 | May 3, 2023 | May 2, 2027 | Philadelphia, PA | usaspending.gov |
| 75N91024D00003 | Department of Health and Human Services | IDC | 541714 | PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM | $0 | $149,995,000 | January 25, 2024 | usaspending.gov | ||
| 75N92E21P00142 | Department of Health and Human Services | Purchase Order | 541715 | THE ELNITSKI LAB IS PURCHASING NORMAL, LIVER, AND PROSTATE CANCER PATIENT PLASMA.[21-004028] | $-16,800 | $0 | May 3, 2021 | May 3, 2021 | Philadelphia, PA | usaspending.gov |
Also on SpecStream
- All recipients under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- All recipients under NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Open opportunities under NAICS 541714
- Open opportunities under NAICS 541715
Public U.S. federal spending data (U.S. Department of the Treasury). Obligations are the contract actions dated in fiscal years 2024 to 2027 of the USAspending.gov award archive of 2026-10-06; a contract's total value is its current value as USAspending reports it, including earlier years. Recipients are matched on their SAM.gov UEI, never on the name, and are shown as the government prints them. Sole proprietorships and opted-out entities count in the totals and are not named. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.